Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT -- Dose-Dependent Liver Activity with No Observed Toxicity Supports IND Pathway

HOTH ALERT: Hoth Therapeutics Reports Positive Preclinical Safety Data for HT-KIT — Dose-Dependent Activity, No Toxicity, IND on DeckHOTH announces strong preclinical data for HT-KIT showing dose-dependent liver activity with zero observed toxicity – key milestone as the company prepares for IND filing.Study Results: Liver weight increased from 1.11g → 1.32g across 0 → 3.0 mg/kg No adverse effects on kidney, spleen, or thymus 100% clean safety profile — no visible lesions or gross pathology Validates safety ...